An important step towards the implementation of the use of genotype information to guide pharmacotherapy is the development of clinical practice guidelines. Several initiatives have been developed to provide these guidelines such as the Clinical Pharmacogenetics Implementation Consortium. Furthermore, several clinical practice recommendations have been published, for example Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions (Epilepsia 2014;55(4):496-506) or Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy (J Popul Ther Clin Pharmacol 2013;20(3):e369-96).
|10. Specific topics|
|Annex 1.||Guidance on conducting systematic revies and meta-analyses of completed comparative pharmacoepidemiological studies of safety outcomes|